Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Deutsch

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Chemical Science|August 2, 2019
Machine learning and molecular descriptors enable rational solvent selection in asymmetric catalysisYehia Amar, Artur M Schweidtmann, Paul Deutsch, et al.
Journal of Clinical Pharmacology|April 23, 2004
Pharmacokinetics of montelukast in asthmatic patients 6 to 24 months oldElizabeth Migoya, Gregory L Kearns, Alan Hartford, et al.
Clinical Pharmacology and Therapeutics|March 7, 2003
Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutinFayez M Hamzeh, Constance Benson, John Gerber, et al.
Antimicrobial Agents and Chemotherapy|November 19, 2002
Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: safety, pharmacokinetics, and antiretroviral activitySharon A Riddler, Diane Havlir, Kathleen E Squires, et al.
Antimicrobial Agents and Chemotherapy|April 24, 2003
Pharmacokinetics of intramuscularly administered ertapenemDonald G Musson, Anup Majumdar, Kimberly Birk, et al.
Cancer Research|May 19, 2005
A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patientsHongyue Dai, Laura van't Veer, John Lamb, et al.
British Journal of Clinical Pharmacology|June 11, 2020
First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G-protein-biased sphingosine-1 phosphate receptor-1 agonist for endothelial protectionLuc Bergougnan, Sara Armani, Georg Golor, et al.
Genomics|November 22, 2005
Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatmentJason S Simon, Maha C Karnoub, David J Devlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2002
Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancerRobert S DiPaola, John Rinehart, John Nemunaitis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancerStephen M Hahn, Eric J Bernhard, William Regine, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Chemical Science|August 2, 2019
Machine learning and molecular descriptors enable rational solvent selection in asymmetric catalysisYehia Amar, Artur M Schweidtmann, Paul Deutsch, et al.
Journal of Clinical Pharmacology|April 23, 2004
Pharmacokinetics of montelukast in asthmatic patients 6 to 24 months oldElizabeth Migoya, Gregory L Kearns, Alan Hartford, et al.
Clinical Pharmacology and Therapeutics|March 7, 2003
Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutinFayez M Hamzeh, Constance Benson, John Gerber, et al.
Antimicrobial Agents and Chemotherapy|November 19, 2002
Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: safety, pharmacokinetics, and antiretroviral activitySharon A Riddler, Diane Havlir, Kathleen E Squires, et al.
Antimicrobial Agents and Chemotherapy|April 24, 2003
Pharmacokinetics of intramuscularly administered ertapenemDonald G Musson, Anup Majumdar, Kimberly Birk, et al.
Cancer Research|May 19, 2005
A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patientsHongyue Dai, Laura van't Veer, John Lamb, et al.
British Journal of Clinical Pharmacology|June 11, 2020
First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G-protein-biased sphingosine-1 phosphate receptor-1 agonist for endothelial protectionLuc Bergougnan, Sara Armani, Georg Golor, et al.
Genomics|November 22, 2005
Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatmentJason S Simon, Maha C Karnoub, David J Devlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2002
Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancerRobert S DiPaola, John Rinehart, John Nemunaitis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancerStephen M Hahn, Eric J Bernhard, William Regine, et al.
Pageof 2